论文部分内容阅读
目的分析来氟米特与甲氨蝶吟联用治疗早期严重类风湿性关节炎的临床治疗效果,评价其安全性及临床应用价值。方法收集我院2008年6月-2010年6月期间收治的早期严重类风湿性关节炎患者共100例,按随机数字方法将患者分为观察组与对照组,每组各50例,观察组给予患者来氟米特与甲氨蝶呤联合治疗,对照组给予患者单一的甲氨蝶呤治疗,对两组患者治疗效果及治疗前后相关临床指标进行观察,进行比较分析。结果观察组患者治疗前后在关节肿胀、关节压痛数、晨僵时间等的差值明显优于对照组,观察组患者治疗的有效率也显著高于对照组,差异均具有统计学意义(P<0.05);两组治疗后患者不良反应无明显差异(P>0.05)。结论来氟米特与甲氨蝶呤联用治疗早期类风湿性关节炎患者,能取得显著的临床疗效,安全可靠,不良反应可耐受,值得临床推广应用。
Objective To analyze the clinical effect of leflunomide and methotrexate in the treatment of early severe rheumatoid arthritis and evaluate its safety and clinical value. Methods A total of 100 patients with early-stage severe rheumatoid arthritis admitted in our hospital from June 2008 to June 2010 were enrolled. Patients were divided into observation group and control group according to random number method, with 50 cases in each group and observation group The combination of leflunomide and methotrexate was given to the patients. The control group was treated with methotrexate alone. The therapeutic effect and the clinical indexes before and after treatment were observed and compared. Results The difference between the observation group and the control group was significantly better than that of the control group before and after treatment, and the difference was statistically significant (P < 0.05). There was no significant difference in adverse reactions between the two groups after treatment (P> 0.05). Conclusion Leflunomide and methotrexate combined treatment of patients with early rheumatoid arthritis, can achieve significant clinical efficacy, safety and reliability, adverse reactions can tolerate, worthy of clinical application.